Review Article Open access Peer reviewed

Advancements in Microbial Drug Discovery: Leveraging AI, CRISPR, and Microbiome Insights to Overcome Antimicrobial Resistance

Authors

Ibrahim Abdulrazaq1https://orcid.org/0009-0001-6107-0331, Shehu-Alimi Elelu2, Ganiyat Omotayo Ibrahim3, Idowu Afeez Temitope4https://orcid.org/0009-0006-5685-9078, Abdulsalam Hawau Avoswahi5, Abdulkareem Tajuddeen Zakari1https://orcid.org/0009-0006-5950-7668, Mustapha Abdulsalam6https://orcid.org/0000-0001-7969-0822
  1. Department of Microbiology, University of Ilorin, Nigeria
  2. Department of Chemistry, Howard University, Washington DC, USA
  3. Department of Chemistry, Nottingham Trent University, UK
  4. Department of Medicinal Research, Kaohsiung Medical University Hospital, Taiwan
  5. Department of Computer Sciences, University of Ilorin, Nigeria
  6. Department of Microbiology, Skyline University, Nigeria
Received
Published
DOI https://doi.org/10.55006/biolsciences.2025.5304 How to Cite Biological Sciences, Vol. 5 No. 3 (2025), 992-1004

Abstract

This study explores the innovative intersection of artificial intelligence (AI), CRISPR technology, and microbiome insights in microbial drug discovery, with a focus on overcoming the challenges posed by antimicrobial resistance (AMR) and emerging infectious diseases. The global threat of AMR necessitates the development of novel approaches that transcend traditional drug discovery methods. AI-driven platforms, including machine learning and high-throughput screening, are transforming drug design by enabling rapid identification of potential therapeutic targets and optimizing drug repurposing efforts. CRISPR-based gene-editing technologies offer precise tools to combat resistance mechanisms at the genetic level, while microbiome-based therapies hold promise for restoring microbial balance and improving immune responses. Despite significant progress, several challenges remain, including the integration of these technologies, data quality concerns, and the clinical translation of innovative solutions. The future of microbial drug discovery lies in the synergy of these technologies, providing a pathway toward personalized, effective treatments and combating the growing threat of AMR. This study provides a comprehensive overview of the current landscape, identifies research gaps, and outlines potential directions for future advancements.

Downloads

Most read articles by the same author(s)

1 2 > >>